Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Many people with HIV fail to regain normal CD4 counts despite effectively suppressing HIV
replication with medications. Blocking the "co-receptor" for HIV might decrease inflammation
of the immune system, potentially providing an immune benefit. The goal of the current trial
is to determine whether adding maraviroc, a new CCR5 "co-receptor" blocker, decreases
inflammation, providing an immune benefit for patients with low CD4 counts despite
undetectable viral loads on HIV medications.
In this study, HIV-infected patients who are receiving antiretroviral therapy for HIV will
receive either maraviroc or a placebo (sugar pill) each day for 24 weeks. After 24 weeks, the
study medication will be stopped and all subjects will be followed for 12 more weeks. Blood
tests measuring the extent of inflammation, low-level viremia, and immune function will be
measured throughout the trial and compared between treatment arms.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
amfAR, The Foundation for AIDS Research Case Western Reserve University Pfizer Rush University Stanford University
Treatments:
Efavirenz HIV Protease Inhibitors Maraviroc Protease Inhibitors Tipranavir